
Christopher E Nelson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6426405/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nature Communications, 2021, 12, 6769.	5.8	73
2	Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nature Medicine, 2019, 25, 427-432.	15.2	303
3	Targeted transcriptional modulation with type I CRISPR–Cas systems in human cells. Nature Biotechnology, 2019, 37, 1493-1501.	9.4	73
4	RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. Nature Communications, 2018, 9, 1674.	5.8	123
5	AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice. JCI Insight, 2018, 3, .	2.3	79
6	Genome engineering: a new approach to gene therapy for neuromuscular disorders. Nature Reviews Neurology, 2017, 13, 647-661.	4.9	68
7	Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. Nature Communications, 2017, 8, 15999.	5.8	53
8	Engineering Delivery Vehicles for Genome Editing. Annual Review of Chemical and Biomolecular Engineering, 2016, 7, 637-662.	3.3	93
9	Cas9 loosens its grip on off-target sites. Nature Biotechnology, 2016, 34, 299-299.	9.4	9
10	In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science, 2016, 351, 403-407.	6.0	957
11	MiRNA inhibition in tissue engineering and regenerative medicine. Advanced Drug Delivery Reviews, 2015, 88, 123-137.	6.6	72